- POSITIVE
Quarterly Revenue Puma biotech Inc Jun-2026 Quarterly Revenue is $57 Million which is growth of 7.8% YoY.
- POSITIVE
Quarterly Net Profit Puma biotech Inc Jun-2026 Quarterly Net Profit is $8 Million which is growth of 39.9% YoY.
9.600.08(0.84%)
327.1K
XNAS Volume
XNAS 18 Sep, 2026 5:30 PM (EDT)
Puma biotech Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents
Forecaster Analyst Estimates for Puma biotech Inc share price target, revenues, EPS, net income and more
Puma biotech Inc quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Rev. | 56.5 | 44.8 | 75.5 | 54.5 | 52.4 | 46 | 59.1 | 80.5 | 47.1 | 43.8 | 72.2 | 56.1 | 54.6 | |
Cost Of Rev. | 12.5 | 10.4 | 23.1 | 12.2 | 12.3 | 10.6 | 13.9 | 29.1 | 10.7 | 10.7 | 24.3 | 13.3 | 11.9 | |
Gross Profit | 44 | 34.4 | 52.3 | 42.3 | 40.1 | 35.5 | 45.2 | 51.5 | 36.4 | 33 | 47.9 | 42.8 | 42.7 | |
| 36.4 | 38.2 | 35.2 | 32.7 | 33.5 | 31.5 | 31.8 | 29.4 | 38.6 | 35.3 | 33.1 | 33.6 | 37.8 | ||
Operating Profit | 7.6 | -3.8 | 17.1 | 9.6 | 6.6 | 4 | 13.4 | 22.1 | -2.2 | -2.3 | 14.8 | 9.2 | 4.9 | |
| 0.7 | 0.3 | -0.1 | -0.5 | -0.9 | -1.1 | -1.4 | -1.8 | -2.1 | -2.4 | -2.6 | -2.7 | -2.7 | ||
Profit Before Tax | 8.2 | -3.4 | 17.1 | 9.2 | 6.2 | 3.3 | 12.2 | 20.6 | -4.2 | -4.6 | 12.8 | 6 | 2.3 | |
Tax | 0.1 | 0.3 | 3.7 | 0.4 | 0.3 | 0.3 | -7.1 | 0.3 | 0.4 | 0.2 | 0.5 | 0.2 | 0.2 | |
| 8.2 | -3.8 | 13.4 | 8.8 | 5.9 | 3 | 19.3 | 20.3 | -4.5 | -4.8 | 12.3 | 5.8 | 2.1 | ||
Diluted NI Avail to Com Stockholders Ann. | 8.2 | -3.8 | 13.4 | 8.8 | 5.9 | 3 | 19.3 | 20.3 | -4.5 | -4.8 | 12.3 | 5.8 | 2.1 | |
Basic EPS | 0.2 | -0.1 | 0.3 | 0.2 | 0.1 | 0.1 | 0.4 | 0.4 | -0.1 | -0.1 | 0.3 | 0.1 | 0.1 | |
Diluted EPS After ExtraOrdinary | 0.2 | -0.1 | 0.3 | 0.2 | 0.1 | 0.1 | 0.4 | 0.4 | -0.1 | -0.1 | 0.3 | 0.1 | 0.1 | |
Number Of Shares End | 50.9 | 50.9 | 50.4 | 50.3 | 49.7 | 49.6 | 49.1 | 49 | 48.3 | 48.2 | 47.6 | 47.5 | 46.8 | |
Net Income Continuing Discontinued Operations | 8.2 | -3.8 | 13.4 | 8.8 | 5.9 | 3 | 19.3 | 20.3 | -4.5 | -4.8 | 12.3 | 5.8 | 2.1 | |
Normalized Income | 8.2 | -3.8 | 13.4 | 8.8 | 5.9 | 3 | 19.3 | 20.3 | -4.5 | -4.8 | 12.3 | 6.4 | 2.1 | |
Interest Income | 0.8 | 1 | 1 | 1 | 1 | 1.1 | 1.2 | 1.3 | 1.2 | 1 | 0.7 | 0.7 | 0.7 | |
Interest | 0.2 | 0.7 | 1.1 | 1.5 | 1.8 | 2.2 | 2.6 | 3.1 | 3.4 | 3.4 | 3.4 | 3.3 | 3.3 | |
Net Interest Income | 0.7 | 0.3 | -0.1 | -0.5 | -0.9 | -1.1 | -1.4 | -1.8 | -2.1 | -2.4 | -2.6 | -2.7 | -2.7 | |
EBIT | 8.4 | -2.7 | 18.2 | 10.7 | 8 | 5.4 | 14.9 | 23.7 | -0.8 | -1.2 | 16.2 | 9.4 | 5.6 | |
EBITDA | 10.9 | -0.1 | 20.9 | 13.5 | 10.8 | 8.2 | 17.7 | 26.6 | 2.1 | 1.7 | 19.1 | 12.2 | 8.5 | |
Reconciled Cost Of Rev. | 12.5 | 10.4 | 23.1 | 12.2 | 12.3 | 10.6 | 13.9 | 29.1 | 10.7 | 10.7 | 24.3 | 13.3 | 11.9 | |
Reconciled Depr. | 2.5 | 2.6 | 2.7 | 2.7 | 2.8 | 2.8 | 2.8 | 2.9 | 2.9 | 2.9 | 2.9 | 2.9 | 2.9 | |
Profit From Continuing Operations | 8.2 | -3.8 | 13.4 | 8.8 | 5.9 | 3 | 19.3 | 20.3 | -4.5 | -4.8 | 12.3 | 5.8 | 2.1 | |
Normalized EBITDA | 10.9 | -0.1 | 20.9 | 13.5 | 10.8 | 8.2 | 17.7 | 26.6 | 2.1 | 1.7 | 19.1 | 12.9 | 8.5 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Puma biotech Inc competitor comparison and performance snapshot within industry
Puma biotech Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Annual Revenue Puma biotech Inc Dec-2025 Annual Revenue is $228 Million which is growth of -0.9% YoY.
- POSITIVE
Annual Net Profit Puma biotech Inc Dec-2025 Annual Net Profit is $31 Million which is growth of 2.8% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | TTM | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.1% | 0.3% | 228.4 | 230.5 | 235.6 | 228 | 253.2 | 225.1 | 272.3 | 251 | 27.7 | |||||
Cost Of Rev. Ann. | 1.8% | 8.1% | 58.2 | 58.2 | 64.4 | 62.7 | 55.1 | 63.7 | 39.4 | 36.8 | 34.6 | 5.6 | - | - | |
Gross Profit Ann. | -0.5% | -1.7% | 173 | 170.2 | 166.1 | 173 | 172.9 | 189.5 | 185.7 | 235.4 | 216.4 | 22.1 | - | - | |
Operating Exp. Ann. | -2.2% | -9.3% | 142.6 | 132.9 | 135.1 | 139.7 | 142.2 | 188.2 | 216.1 | 273.4 | 311 | 314.5 | 276.6 | 240.3 | |
Operating Profit Ann. | 6.7% | - | 30.4 | 37.3 | 31 | 33.3 | 30.7 | 1.3 | -30.4 | -37.9 | -94.7 | -292.4 | -276.6 | -240.3 | |
- | - | 0.3 | -2.5 | -7.7 | -10.7 | -10.8 | -12.7 | -13.6 | -12.2 | -9.2 | 0.5 | 1 | 1 | ||
Other Exp. Ann. | - | - | 1 | 0.9 | 0.1 | -19.5 | -17.4 | -15.8 | -25.5 | -9.7 | -0.1 | -0.4 | 0 | ||
PBT Ann. | 315.2% | - | 31.2 | 35.8 | 24.1 | 22.7 | 0.5 | -28.8 | -59.8 | -75.6 | -113.6 | -292 | -276 | -239.3 | |
Tax Ann. | 111% | 88% | 4.5 | 4.7 | -6.2 | 1.1 | 0.5 | 0.3 | 0.2 | - | - | - | - | - | |
- | - | 26.7 | 31.1 | 30.3 | 21.6 | -29.1 | -60 | -75.6 | -113.6 | -292 | -276 | -239.3 | |||
Diluted NI Avail to Com Stockholders Ann. | - | - | 26.7 | 31.1 | 30.3 | 21.6 | -29.1 | -60 | -75.6 | -113.6 | -292 | -276 | -239.3 | ||
EPS Ann. | - | - | 0.6 | 0.6 | 0.5 | -0.7 | -1.5 | -2 | -3 | -7.9 | -8.3 | -7.5 | |||
Diluted EPS Ann. | - | - | 0.6 | 0.6 | 0.5 | -0.7 | -1.5 | -2 | -3 | -7.9 | -8.3 | -7.5 | |||
Number Of Shares End | 3.2% | 4.8% | 50.4 | 49.1 | 47.6 | 45.8 | 41 | 39.9 | 39.1 | 38.2 | 37.5 | 35.7 | 32.5 | ||
Total Exp. Ann. | -1.1% | -5.6% | 191.1 | 199.5 | 202.4 | 197.3 | 251.9 | 255.5 | 310.2 | 345.7 | 320.1 | 276.6 | 240.3 | ||
Net Income Continuing Discontinued Operations Ann. | - | - | 26.7 | 31.1 | 30.3 | 21.6 | -29.1 | -60 | -75.6 | -113.6 | -292 | -276 | -239.3 | ||
Normalized Income Ann. | 26.4% | - | 26.7 | 31.1 | 30.3 | 22.2 | 15.4 | -16.2 | -48.2 | -50 | -104.6 | -292 | -276 | -239.3 | |
Interest Income Ann. | 72.4% | 52.3% | 3.9 | 4.1 | 4.7 | 2.6 | 0.8 | 0.2 | 0.5 | 2.9 | 1.8 | 1.3 | 1 | 1 | |
Interest Ann. | -17.1% | -14.1% | 3.5 | 6.6 | 12.5 | 13.3 | 11.6 | 12.8 | 14.1 | 15 | 11 | 0.7 | - | - | |
EBITDA Ann. | 36.4% | - | 45.2 | 53.3 | 48.1 | 47.5 | 21 | -5.4 | -35.7 | -52.5 | -95.2 | -288.4 | -275.5 | -239.5 | |
Reconciled Cost Of Rev. Ann. | 1.8% | 8.1% | 58.2 | 58.2 | 64.4 | 62.7 | 55.1 | 63.7 | 39.4 | 36.8 | 34.6 | 5.6 | - | - | |
Reconciled Depr. Ann. | 7% | 1.7% | 10.5 | 10.9 | 11.5 | 11.5 | 8.9 | 10.6 | 10 | 8.1 | 7.4 | 2.8 | 1.2 | 0.8 | |
Profit From Continuing Operations Ann. | - | - | 26.7 | 31.1 | 30.3 | 21.6 | -29.1 | -60 | -75.6 | -113.6 | -292 | -276 | -239.3 | ||
Normalized EBITDA Ann. | 9.7% | - | 45.2 | 53.3 | 48.1 | 48.2 | 40.4 | 12.3 | -19.5 | -26.9 | -86.2 | -288.4 | -275.5 | -239.5 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
-0.9%
2Y CAGR
-1.5%
3Y CAGR
0.1%
5Y CAGR
0.3%
7Y CAGR
-1.3%
Total Revenue Annual is falling faster than historical averages.
Net Profit Ann.
1Y CHG
2.6%
2Y CAGR
20%
Net Profit Annual growth is lower than historical averages.
Operating Exp. Ann.
1Y CHG
-1.6%
2Y CAGR
-2.5%
3Y CAGR
-2.2%
5Y CAGR
-9.3%
7Y CAGR
-11.4%
10Y CAGR
-5.8%
Operating Expenses Annual Cr is falling slower than historical averages.
Puma biotech Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Total Shareholders Fund Puma biotech Inc Dec-2025 Total Shareholders Fund is $130 Million which is growth of 41.5% YoY.
- POSITIVE
Total Assets Puma biotech Inc Dec-2025 Total Assets is $216 Million which is growth of 1.4% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.9% | -2.4% | 216.3 | 213.3 | 230.5 | 222.1 | 226.6 | 244.2 | 234.9 | 259.1 | 165.5 | 252.8 | 239.8 | ||
-24.6% | -19.2% | 86 | 121.2 | 177.1 | 200.5 | 229 | 250.2 | 217.4 | 224.8 | 112.2 | 43 | 33.8 | ||
82% | - | 130.3 | 92.1 | 53.4 | 21.6 | -2.5 | -6 | 17.5 | 34.3 | 53.3 | 209.8 | 206 | ||
Total Capitalization Ann. | 2.8% | 10.8% | 130.3 | 113.8 | 119.1 | 119.9 | 94.7 | 78.1 | 112.4 | 186.2 | 101.8 | 209.8 | 206 | |
Tangible Assets Ann. | - | - | 89 | 41 | -7.4 | -49 | -68.6 | -80.1 | -23 | -10.1 | 5 | 209.8 | 206 | |
Working Capital Ann. | 12.7% | 20.6% | 81.4 | 51.6 | 56.8 | 56.8 | 30.4 | 31.9 | 75.5 | 135.9 | 48.1 | 199 | 191.1 | |
Invested Capital Ann. | 8.4% | 10.6% | 152.9 | 159.2 | 153.1 | 119.9 | 94.7 | 92.4 | 112.4 | 186.2 | 101.8 | 209.8 | 206 | |
Tangible Book Value Ann. | - | - | 89 | 41 | -7.4 | -49 | -68.6 | -80.1 | -23 | -10.1 | 5 | 209.8 | 206 | |
Borrowings Ann. | -37% | -25.1% | 28.6 | 74.1 | 111.5 | 114.3 | 116.6 | 121 | 120.2 | 151.9 | 48.5 | - | - | |
Net Debt Ann. | - | - | - | - | 15.1 | 22.1 | 34 | 13 | 34.9 | 43.5 | - | - | - | |
Share Issued Ann. | 2.8% | 4.7% | 50.4 | 49.1 | 47.7 | 46.4 | 41.2 | 40.1 | 39.2 | 38.3 | 37.6 | 36.8 | 32.5 | |
Number Of Shares End | 3.2% | 4.8% | 50.4 | 49.1 | 47.6 | 45.8 | 41 | 39.9 | 39.1 | 38.2 | 37.5 | 35.7 | 32.5 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
1.4%
2Y CAGR
-3.1%
3Y CAGR
-0.9%
5Y CAGR
-2.4%
7Y CAGR
-2.5%
10Y CAGR
-1%
Total Assets Annual growth is higher than historical averages.
Total Current Liabilities Ann.
1Y CHG
-15.4%
2Y CAGR
-9.6%
3Y CAGR
1.6%
5Y CAGR
-6.6%
7Y CAGR
2.8%
10Y CAGR
9.6%
Total Current Liabilities Annual Cr is falling faster than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
41.5%
2Y CAGR
56.2%
3Y CAGR
82%
7Y CAGR
21%
10Y CAGR
-4.5%
Total ShareHolders Funds Annual growth is stable compared to historical averages.
Puma biotech Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Book Value Per Share Puma biotech Inc Book Value Per Share is $3 which is growth of 29.1% YoY.
- NEUTRAL
ROE Puma biotech Inc ROE is 0% which is growth of 0% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RoA Ann. % | - | - | - | 13.64% | 9.54% | -12.37% | -25.04% | -30.60% | -53.49% | -139.59% | -112.06% | -118.87% | ||
ROE Ann. % | - | - | - | 41.60% | 57.54% | 0.02% | - | -1,042.30% | -292.05% | -259.28% | -221.91% | -132.75% | -148.14% | |
ROIC % | - | - | - | 12.6 | 9.4 | -2.5 | - | - | -6.3 | -15.6 | -56.1 | -48.4 | -27.5 | |
OPM Ann. % | 6.6% | - | 16.33% | 13.44% | 14.12% | 13.47% | 0.51% | -13.51% | -13.93% | -37.72% | -1,056.13% | - | - | |
Inventory Turnover Ratio Ann. | - | - | - | 8.2 | 10.8 | 9.5 | 12.1 | 11.9 | 12.7 | 14.9 | 2.8 | - | - | |
Asset Turnover Ann. % | - | - | - | 1 | 1 | 1 | 1.1 | 0.9 | 1.1 | 1.2 | 0.1 | - | - | |
Working Capital Turnover Ann. | -11.2% | -17% | 2.8 | 4.5 | 4.2 | 4 | 8.3 | 7.1 | 3.6 | 1.9 | 0.6 | |||
Quick Ratio Ann. | - | - | - | 1.4 | 1.5 | 1.6 | 1.1 | 1 | 1.6 | 2.8 | 1.6 | 6.1 | 6.7 | |
Current Ratio Ann. | - | - | - | 1.5 | 1.6 | 1.7 | 1.3 | 1.3 | 1.8 | 3 | 1.8 | 6.3 | 6.9 | |
Interest Coverage Ratio Ann. | - | - | - | 2.9 | 2.7 | 1 | -1.3 | -3.3 | -4 | -9.3 | -404.5 | - | - | |
LT Debt To Equity Ann. | - | - | - | 0.3 | 1.4 | 5.1 | - | - | 6.7 | 4.4 | 0.9 | - | - |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Puma biotech Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Cash From Operating Activity Puma biotech Inc Dec-2025 Cash From Operating Activity is $42 Million which is growth of 7.4% YoY.
- NEGATIVE
Net Cash Flow Puma biotech Inc Dec-2025 Net Cash Flow is $-40 Million which is growth of -157.6% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
- | 120.6% | 41.8 | 38.9 | 27 | -15.8 | 20.7 | 0.8 | 22.4 | -24.1 | -172.5 | -141.7 | -154.5 | ||
- | - | -36.2 | -20.4 | -19.1 | 7.1 | -10.9 | 23.4 | 5.2 | -57.6 | -15.4 | 142.2 | -85.9 | ||
- | - | -45.2 | -33.9 | 12.2 | -31.9 | 0.1 | -67.1 | 108.5 | 75.1 | 162.4 | 233.4 | |||
Cash Plus Cash Eqv. End Of Year Ann. | -26.2% | -20.1% | 31.7 | 71.3 | 86.7 | 78.8 | 75.3 | 97.5 | 73.2 | 112.7 | 81.7 | 194.5 | 31.6 | |
Net Increase In Cash Plus Cash Eqv.s Ann. | - | - | -39.6 | -15.4 | 7.9 | 3.5 | -22.2 | 24.2 | -39.5 | 26.7 | -112.8 | 162.9 | -7 | |
Cash Plus Cash Eqv. Begin Of Year Ann. | -1.8% | -0.5% | 71.3 | 86.7 | 78.8 | 75.3 | 97.5 | 73.2 | 112.7 | 86 | 194.5 | 31.6 | 38.5 | |
Income Tax Paid Supplemental Data Ann. | 55.4% | 49.6% | 1.5 | 1.2 | 0.7 | 0.4 | 0.3 | 0.2 | - | - | - | - | - | |
Interest Paid Supplemental Data Ann. | -17.4% | -9.8% | 5.8 | 10.8 | 11.6 | 10.3 | 10.3 | 9.7 | 11.7 | 8.1 | 0.3 | - | - | |
Capex Ann. | - | - | -0.1 | -0.1 | -12.6 | -7 | - | -20.1 | -0.3 | -0.6 | -50.4 | -7.3 | -1.2 | |
Issuance Of Capital Stock Ann. | - | - | - | 12.5 | - | - | - | 161.9 | 205.1 | |||||
Issuance Of Debt Ann. | - | - | - | - | 98.5 | 8.4 | 25 | 105 | 50 | - | - | |||
Repayment Of Debt Ann. | - | - | -44.4 | -33.3 | -100 | -8.4 | -80 | - | - | - | - | |||
Repurchase Of Capital Stock Ann. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Free Cash Flow Ann. | - | - | 41.7 | 38.9 | 14.4 | -22.8 | 20.7 | -19.3 | 22.1 | -24.7 | -222.9 | -149 | -155.7 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Operating Act. Ann.
1Y CHG
7.5%
2Y CAGR
24.4%
5Y CAGR
120.6%
Cash from Operating Activity Annual growth is lower than historical averages.
